Process for the Production of Recombinant Activated Human Protein C for the Treatment of Sepsis

• 1. 用于生产治疗脓毒症的重组人活化蛋白C的、包含密码子优化的方法 [P] . 中国专利： CN101228269A . 2008-07-23
• 2. SLAMF7重组蛋白在制备治疗脓毒症药物中的应用 [P] . 中国专利： CN112538526A . 2021-03-23
• 3. A PROCESS COMPRISING CODON OPTIMIZATION FOR THE PRODUCTION OF RECOMBINANT ACTIVATED HUMAN PROTEIN C FOR THE TREATMENT OF SEPSIS. [P] . MX2007014674A . 2008-03-07

  机译： 包含密码子优化的过程，用于生产重组活性蛋白C以治疗脓毒症。

• 4. A PROCESS COMPRISING CODON OPTIMIZATION FOR THE PRODUCTION OF RECOMBINANT ACTIVATED HUMAN PROTEIN C FOR THE TREATMENT OF SEPSIS [P] . IL187477D0 . 2008-03-20

  机译： 包含密码子优化的过程的生产重组活性蛋白C，用于脓毒症的治疗

• 5. A PROCESS COMPRISING CODON OPTIMIZATION FOR THE PRODUCTION OF RECOMBINANT ACTIVATED HUMAN PROTEIN C FOR THE TREATMENT OF SEPSIS [P] . IL187477A . 2008-03-20

  机译： 包含密码子优化的过程的生产重组活性蛋白C，用于脓毒症的治疗

• 1. Optimization of Fermentation Process for Human-like Collagen Production of Recombinant Escherichia coli Using Response Surface Methodology [J] . 张驰, 范代娣, 尚龙安, 中国化学工程学报：英文版 . 2010,第001期
• 2. THE ROLE OF RECOMBINANT HUMAN FUSION PROTEIN IL-6／IL-2 （CH925） IN HEPADNA VIRUS INFECTION TREATMENT [J] . 米志宝, 赵春华, 张习坦, 中国医学科学杂志：英文版 . 1995,第004期
• 3. Human ovarian neoplasm cell CD147 stimulates production and activation of matrix metalloproteinases in co-cultures with mouse fibroblasts [J] . YANG Hong, ZOU Wei, XIN Xiao-yan 中国人民解放军军医大学学报（英文版） . 2005,第001期
• 4. Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach [J] . Zhongheng Zhang BMJ Open . 2014,第7期
• 5. Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach [J] . Zhongheng Zhang BMJ Open . 2014,第7期
• 6. Adventure of Recombinant Human Activated Protein C in Sepsis and New Treatment Hopes on the Horizon [J] . Selcuk Kaya Recent Patents on Inflammation & Allergy Drug Discovery . 2012,第2期
• 7. Characterization of the Novel Human AGE1hn Cell Line for Production of Recombinant Proteins [C] . S. Northoff, H. Biintemeyer, V. Sandig, European Society of Animal Cell Technology . 2010
• 8. Development of plant cell suspension cultures as a bioproduction platform for recombinant human therapeutic proteins [D] . Huang, Ting-Kuo 2009
• 9. Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach [O] . Zhongheng Zhang 2014
• 10. Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis [O] . Garber, Gary, Gibney, RT Noel, Light, Bruce, 2002

• 1. BACKGROUND： Vibrio vulnifi cus inside the body could activate the NF-!B signaling pathwayand initiate the inflammatory cascade. The lung is one of the earliest organs affected by sepsisassociated with acute lung injury. High mobility group protein B1 （HMGB1） is an important late-actingpro-infl ammatory cytokine involving in the pathophysiology of sepsis. It is also involved in the injuryprocess in the lung, liver and intestine. There has been no report on the involvement of HMGB1 inVibrio vulnifi cus sepsis-induced lung injury.METHODS： Sixty rats were randomly divided into a normal control group （group A, n=10） anda Vibrio vulnificus sepsis group （group B, n=50）. Sepsis was induced in the rats by subcutaneousinjection of Vibrio vulnificus （concentration 6×108 cfu/mL, volume 0.1 mL/100g）） into the left lowerlimbs. The rats in group B were sacrifi ced separately 1, 6, 12, 24, and 48 hours after the infection.Their lungs were stored as specimens, lung water content was measured, and lung pathology wasobserved under a light microscope. The expressions of the HMGB1 gene and protein in the lungswere detected by RT-PCR and Western blot. Data were analyzed with one-way analysis of variance（ANOVA） and the LSD method for pair-wise comparison between the two groups. P〈0.05 wasconsidered statistically signifi cant.RESULTS： Compared to group A （0.652±0.177）, HMGB1 mRNA expression in the lungs ofgroup B was signifi cantly higher at 0 hour （1.161±0.358, P=0.013）, 24 hours （1.679±0.235, P=0.000）,and 48 hours （1.258±0.274, P=0.004） （P〈0.05）, and peaked at 24 hours. Compared to group A（0.594±0.190）, HMGB1 protein expression at 6 hours （1.408±0.567, P=0.026） after infection wassignificantly increased （P〈0. 05）, and peaked at 24 hours （2.415±1.064, P=0.000） after infection.Compared to group A （0.699±0.054）, lung water content was significantly increased at 6 hours（0.759±0.030, P=0.001）,12 hours （0.767±0.023, P=0.000）, 24 hours （0.771±0.043, P=0.000） and 48hours （0.789±0.137, P=0.000） after infection （P〈0.05）. Compared to group A, pathological changesat 12 hours in group B indicate marked pulmonary vascular congestion, interstitial edema andinfl ammatory infi ltration. Alveolar cavity collapse and boundaries of the alveolar septum could not beclearly identifi ed.CONCLUSION： Vibrio vulnifi cus sepsis can lead to injury in rat lungs, and increased HMGB1expression in lung tissue may be one of the mechanisms for injury from Vibrio vulnifi cus sepsis. [J] . Qiao-meng Qiu ,Zhong-wang Li ,Lu-ming Tang . 世界急诊医学杂志(英文) . 2011,第4期
• 2. Effects of recombinant human canstatin protein in the treatment of pancreatic cancer [J] . Xiao-Ping He ,Zhao-Shen Li ,Ren-Min Zhu . 世界胃肠病学杂志：英文版 . 2006,第41期
• 3. 基因重组活化人凝血因子Ⅶ治疗抑制物阳性的血友病出血的效果评估 [C] . 漆雩 ,华宝来 ,赵永强 . 中华医学会第十三次全国内科学学术会议 . 2011
• 4. 基于防御素的巨胞饮介导重组融合蛋白以及双靶向单链抗体重组融合蛋白的制备和抗肿瘤活性研究 [A] . 杜玥 . 2016